Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 20/20 | 0.80 |
| ▸ | INSR | P06213 | 11/20 | 0.80 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.80 |
| ▸ | PLK4 | O00444 | 1/20 | 0.74 |
| ▸ | BUB1B | O60566 | 1/20 | 0.74 |
| ▸ | JAK2 | O60674 | 1/20 | 0.74 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.74 |
| ▸ | ABL1 | P00519 | 1/20 | 0.74 |
| ▸ | EGFR | P00533 | 1/20 | 0.74 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.74 |
| ▸ | LCK | P06239 | 1/20 | 0.74 |
| ▸ | NPM1 | P06748 | 1/20 | 0.74 |
| ▸ | FES | P07332 | 1/20 | 0.74 |
| ▸ | LYN | P07948 | 1/20 | 0.74 |
| ▸ | RET | P07949 | 1/20 | 0.74 |
| ▸ | IGF1R | P08069 | 1/20 | 0.74 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.74 |
| ▸ | MET | P08581 | 1/20 | 0.74 |
| ▸ | ROS1 | P08922 | 1/20 | 0.74 |
| ▸ | FGR | P09769 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31521764 | 1.00 | ALK (0.80) | ALKINSRKCNH2PLK4BUB1B | |
| SCHEMBL28630275 | 0.96 | ALK (0.81) | ALKINSRKCNH2PLK4BUB1B | |
| SCHEMBL30761514 | 0.96 | ALK (0.81) | ALKINSRKCNH2PLK4BUB1B | |
| SCHEMBL30180184 | 0.95 | ALK (0.80) | ALKINSRKCNH2PLK4BUB1B | |
| SCHEMBL28619835 | 0.94 | ALK (0.77) | ALKINSRKCNH2PLK4BUB1B | |
| SCHEMBL30180204 | 0.93 | ALK (0.75) | ALKINSRKCNH2 | |
| SCHEMBL17879562 | 0.93 | ALK (0.73) | ALKINSRKCNH2PLK4BUB1B | |
| SCHEMBL28624667 | 0.93 | ALK (0.75) | ALKINSRKCNH2PLK4BUB1B | |
| SCHEMBL28622455 | 0.93 | ALK (0.79) | ALKINSRKCNH2PLK4BUB1B | |
| SCHEMBL29202721 | 0.92 | ALK (0.84) | ALKINSRKCNH2PLK4BUB1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044323-A1 | DEUTERATED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS | SUZHOU ZELGEN BIOPHARMACEUTICALS CO LTD (CN) | 2018-02-15 | — | — | US | disclosed |
| US-9809572-B2 | Deuterated diaminopyrimidine compounds and pharmaceutical compositions comprising such compounds | SUZHOU ZELGEN BIOPHARMACEUTICALS CO., LTD. (CN) | 2017-11-07 | — | — | US | disclosed |
| WO-2017041771-A1 | PROCESS FOR THE PREPARATION OF CERITINIB USING \"IN SITU\" PREPARED 5-METHYL-2-(1 -METHYLETHOXY)-4-(4-PIPERIDINYL)-BENZENAMINE MONOHYDROCHLORIDE (1 :1 ) AS AN INTERMEDIATE | ZENTIVA, K.S. (CZ) | 2017-03-16 | — | — | WO | disclosed |
| EP-3012249-A1 | COMPOUNDS AND COMPOSITION AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| US-9296721-B1 | Method for preparing ALK inhibitor ceritinib | XU YONG (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296721-B1 | Method for preparing ALK inhibitor ceritinib | XU YONG (US) | 2016-03-29 | — | — | US | disclosed |
| EP-2271630-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-03-23 | — | — | EP | disclosed |
| EP-2311807-B1 | Compounds and composition as protein kinase inhibitors | NOVARTIS AG (CH) | 2015-11-11 | — | — | EP | disclosed |
| US-20150105390-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2015-04-16 | — | — | US | disclosed |
| US-8957081-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2015-02-17 | — | — | US | disclosed |
| EP-2537830-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-12-26 | — | — | EP | disclosed |
| US-20110257154-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-10-20 | — | — | US | disclosed |
| US-20110257155-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-10-20 | — | — | US | disclosed |
| US-8039479-B2 | Such as 6-{5-Chloro-4-[2-(propane-2-sulfonyl)-phenylamino]-pyrimidin-2-ylamino}-5-isopropoxy-2-piperidin-4-yl-2,3-dihydro-isoindol-1-one; tumors, cancer; inhibition of anaplastic lymphoma, focal adhesion, zeta chain associated protein 70 and/or insulin like growth factor | IRM LLC (BM) | 2011-10-18 | — | — | US | disclosed |
| US-20110190259-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-08-04 | — | — | US | disclosed |
| US-20110135668-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-06-09 | — | — | US | disclosed |
| EP-2311807-A1 | Compounds and composition as protein kinase inhibitors | IRM LLC (BM) | 2011-04-20 | — | — | EP | disclosed |
| EP-2271630-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009126515-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-10-15 | — | — | WO | disclosed |
| US-20080176881-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135668-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ROS1, INSR, IGF1R | ALK 6/4885INSR 2/4885KCNH2 2061/4885 |
| US-20080176881-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | ALK 23/4885INSR 67/4885KCNH2 2126/4885 |
| US-20180044323-A1 | DEUTERATED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS | DCK, DPYD, BRAF | ALK 1210/4885INSR 2231/4885KCNH2 2496/4885 |
| US-20110190259-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | ALK 23/4885INSR 67/4885KCNH2 2126/4885 |
| US-20150105390-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | ALK 23/4885INSR 67/4885KCNH2 2126/4885 |
| US-20110257154-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | ALK 23/4885INSR 67/4885KCNH2 2126/4885 |
| US-20110257155-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | ALK 23/4885INSR 67/4885KCNH2 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.